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Abstract
Introduction
Salmonella Typhi is one of the leading health problems in Pakistan. With the emergence of
extensively drug resistant (XDR) Salmonella Typhi, treatment options are limited. Here we
report the clinical manifestations and the response to treatment of patients with XDR
Typhoid fever. The patients were treated with either Meropenem or Azithromycin or a combi-
nation of both.
Methods
We reviewed the records of culture confirmed XDR typhoid who visited Aga Khan University
Hospital (AKUH), Karachi and Aga Khan Secondary Care Hospital, Hyderabad from April
2017 to June 2018. Symptoms developed during disease, unplanned treatment extension
and complications developed while on antimicrobials was recorded. Means with standard
deviation were calculated for duration of treatment, time to defervescence, and cost of
treatment.
Results
Records of 81 culture confirmed XDR typhoid patients admitted at the AKU hospitals were
reviewed. Most, (n = 45; 56%) were male. Mean age of the cases was 8.03 years with range
(1–40). About three quarter (n = 66) of the patients were treated as inpatient. Fever and
vomiting were the most common symptoms at the time of presentation. Oral azithromycin
alone (n = 22; 27%), intravenous meropenem alone (n = 20; 25%), or a combination of azi-
thromycin and meropenem (n = 39; 48%) were the options used for treatment. Average
(95% confidence interval) time to defervescence was 7.1(5.5–8.6), 6.7(4.7–8.7), and 6.7
(5.5–7.9) days for each treatment option respectively whereas there were 1,0 and 3 treat-
ment failures in each treatment option respectively. Average cost of treatment per day for
azithromycin was US$5.87 whereas it was US$88.46 for meropenem.
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Conclusion
Patients treated with either Azithromycin, Meropenem alone or in combination showed simi-
lar time to defervescence. Because of the lower cost of azithromycin, it is preferable in lower
socio-economic areas. Background estimates for power calculation can be made for more
robust clinical trials using this observational data.
Author summary
Ever since the emergence of Extensively Drug Resistant (XDR) Typhoid fever in Paki-
stan, which is resistant to all but two classes of anti-microbials, we need to find an effec-
tive treatment plan so that S.Typhi does not also make these anti-microbials redundant
in the future. In this retrospective case series review, we observed the response of XDR
Typhoid fever patients treated with meropenem or azithromycin or combination of
both. All 3 groups showed a similar therapeutic response based on number of complica-
tions developed and time taken for fever clearance. The higher price of meropenem
however could become a deterrent to its use in poor socio-economic areas. This new
knowledge may contribute to better treatment plans in handling XDR enteric fever in
the future whilst also serving as a rough guide in how to treat patients with XDR
Typhoid fever in the present.
Introduction
Typhoid fever is a systemic infection caused by the Salmonella enterica serovar Typhi (S.
Typhi). According to the World Health Organisation (WHO), estimates of burden of typhoid
fever range between 11 and 21 million cases and roughly 128 000 to 161 000 deaths annually
[1]. Typhoid fever is a disease of low and middle-income countries but with the emergence of
antimicrobial resistance and increase in international travel, the threat is now global[2]. In the
last two decades several outbreaks of multi-drug resistant (MDR) S.Typhi of H58 genotype
have been reported from various parts of the world[3,4]. These organisms are a major threat to
typhoid treatment as they are resistant to the first line antimicrobials; ampicillin, chloram-
phenicol, and trimethoprim-sulfamethoxazole. Similarly, resistance to fluoroquinolones has
also increased over the same period. Consequently, third-generation cephalosporins, particu-
larly ceftriaxone, have become the antimicrobials of choice for typhoid treatment in endemic
countries[5,6].
In November 2016, a large outbreak of ceftriaxone-resistant typhoid fever started in
Hyderabad city of southern Pakistan. The associated organism was a H58 S.Typhi exhibiting
resistance to five classes of antimicrobials (chloramphenicol, ampicillin, trimethoprim-sul-
famethoxazole, fluoroquinolones, and third-generation cephalosporins) and was conse-
quently labeled as extensively drug-resistant (XDR) S.Typhi[7,8]. This strain of XDR S.
Typhi was sensitive to azithromycin and meropenem. The outbreak first started in Hydera-
bad city with it quickly spreading to the adjacent cities including Karachi. As of August,
2019, more than 10,000 cases of XDR Typhoid have been reported from Hyderabad and
Karachi alone[9].
Owing to the novelty of XDR S.Typhi, no treatment guidelines are available yet globally.
Treatment options are limited and no data on treatment outcomes of XDR Typhoid is avail-
able. The data we have is much needed for the development of treatment protocols for XDR
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Typhoid patients. Moreover, observational data from this study may also be helpful in design-
ing a more robust clinical trial for the treatment of XDR Typhoid in the future.
Methods
Study setting and population
A retrospective review of XDR Typhoid cases was conducted in two hospitals; Aga Khan Uni-
versity Hospital (AKUH) in Karachi and Aga Khan Maternal and Child Centre (AKMCC) in
Hyderabad. AKUH is a 740-bed private tertiary care teaching hospital located in the metropol-
itan city of Karachi while AKMCC is a private secondary care hospital catering only to mothers
and children, located in the city of Hyderabad. Karachi and Hyderabad are located about 150
kilometers away from each other in the province of Sindh, Pakistan.
Patients with a diagnosis of blood culture confirmed XDR S.Typhi were identified from the
registry of both hospitals. Hospital records of typhoid patients treated as either inpatient or
outpatient during 1st April 2017 to 30th June 2018 were reviewed for screening to be included
in this study. Typhoid patients with blood culture confirmation for S.Typhi and resistance to
the five classes of antibiotics (ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole,
fluoroquinolone, and 3rd generation cephalosporin (ceftriaxone or cefixime) were eligible to
be included in this study. Patients with incomplete medical records especially missing infor-
mation on antimicrobial treatment, duration of treatment, treatment failure, and time to
defervescence were excluded from the study. Also, patients who left against medical advice
(LAMA) within 2 days of admission, those who had a positive blood culture but did not seek
treatment at either hospital or those who did not return for follow-up visit in clinic after the
confirmation of blood culture testing were excluded. A total of 142 records with the diagnosis
of typhoid were screened and only 81 records which fulfilled the eligibility criteria were
included in this study (Fig 1).
Data collection tool and operational definitions
We used a structured tool in English language to extract information from the medical rec-
ords. The tool was composed of variables such as demographic characteristics (age, gender),
symptoms including fever at the time of presentation to the hospital/clinic, blood culture and
antimicrobial sensitivity findings, time in days to defervescence, complications (if any) of dis-
ease process, type and duration of antimicrobial therapy, side effects (if any) and treatment
Fig 1. Flow chart of patient inclusion, exclusion and distribution for study population. XDR extensively drug
resistant. LAMA, leave against medical advice.
https://doi.org/10.1371/journal.pntd.0008682.g001
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failure. Clinical response of antimicrobial therapy was defined as time taken for defervescence
(time from first recording of fever, either inpatient or outpatient, till return of body tempera-
ture to less than 380 C for more than 48 hours). Treatment failure was defined as either relapse
of disease within 30 days of treatment completion, or development of complications while on
therapy (septic shock, meningitis, death, hepatitis etc.[10]), or extension of duration of antimi-
crobial therapy beyond 14 days for meropenem and 10 days for azithromycin. Cost of pur-
chase of anti-microbials was calculated for maximum dosages that could theoretically be given.
This meant that meropenem cost was calculated for 2g every 8 hours while azithromycin cost
was calculated for 1g every 24 hours. No other direct or indirect costs were measured.
Ethical considerations
This study was conducted as a part of a larger study which involved investigation of the out-
break of XDR Typhoid and control interventions in Hyderabad and Karachi. The larger study
was approved by ethical review committee (ERC) of Aga Khan University Karachi, Pakistan
and national bioethics committee (NBC) of Pakistan. For this specific part of the study which
involved retrospective review of hospital records, we submitted it for an ERC exemption
which was granted.
Data management and analysis
Two research assistants entered the data independently using the statistical package for social
scientists (SPSS) version 25.0. The two datasets were compared to assess for any typographic/
data entry errors, validated against the corresponding hard copy of the data tools and cor-
rected. Data was also checked for missing information on the essential variables such as anti-
microbial treatment, duration of treatment and time to defervescence. Any variable with
extreme values or illogical values were validated against the corresponding physical data tool
and the actual medical record files. Frequencies with percentages were calculated for categori-
cal variables such as gender, type of treatment, place (hospital) of treatment, and inpatient ver-
sus outpatient treatment. In addition, means with standard deviation were calculated for
continuous variables such as age in years, duration of treatment, and time to defervescence etc.
Cost of treatment per day for each type of antimicrobial therapy was also calculated and com-
pared across the groups.
Results
Out of 81 records reviewed for this study, 47(58%) were from AKMCC. About three quarter
(n = 66; 81%) of XDR Typhoid patients were treated as inpatient. Slightly more than half
(n = 45; 56%) of the patients were male and average age of the patients was 8.0 years with
range (1–40) (Fig 2). Average temperature at the time of presentation in the hospital was 38.5
±0.89 (Range = 40.0–36.0) 0C. 64% (n = 52) of patients in this study were started on empirical
anti-microbial therapy prior to presentation; either self-prescribed or on the recommendation
of a physician (Table 1).
Fever (n = 81; 100%) and vomiting (n = 53; 65%) were the most common symptoms devel-
oped during course of disease, followed by diarrhea (47%), abdominal pain (43%) and head-
ache (38%) (Fig 3).
Out of 81 XDR Typhoid patients, 22 (27%) were treated with azithromycin alone, 20 (25%)
with meropenem alone and 39 (48%) received a combination of azithromycin and merope-
nem. Patients who received meropenem only were all treated as inpatient, whereas only 11/22
(50%) patients treated with azithromycin required hospitalization. Meropenem was given
Intravenously (IV) at a dose of 20-40mg/kg three times a day while azithromycin was given
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orally at 20mg/kg/day. There was only one treatment failure among patients treated with azi-
thromycin while on the other hand three treatment failures each were observed among the
patients treated with combination of azithromycin and meropenem. No treatment failure was
seen in patients treated with meropenem. Average time in days (95% confidence interval) to
defervescence was 7.1(5.5–8.6) for azithromycin, 6.7(4.7–8.7) for meropenem, and 6.7(5.5–
7.9) for combination of meropenem and azithromycin. Average time to defervescence was
lower for the patients treated with meropenem and combination of azithromycin and merope-
nem as compared to the patients treated with azithromycin (Fig 4). Average daily cost of treat-
ment was highest (US$94.33) for the patients receiving combination of azithromycin and
meropenem and lowest (US$5.87) for those treated with azithromycin alone (Table 2).
Discussion
In this study we assessed the response of azithromycin and meropenem–either alone or in
combination, for the treatment of XDR Typhoid fever. All three treatment options were highly
effective, with less than 5% treatment failure in each group, however patients treated with mer-
openem had no treatment failure. Patients treated with meropenem and combination of azi-
thromycin and meropenem had a slightly earlier time to defervescence.
Table 1. Demographic characteristics and treatment of culture proven XDR Typhoid patients (N = 81).
Patient characteristics Frequency (%)
Centers�
AKUH
AKMCCC
34 (42.0%)
47 (58.0%)
Age in years at diagnosis (Mean)
(Min–Max)
8.03
1–40
Gender (Male) 45 (56.0%)
Patients treated as Inpatients 66 (81.0%)
Fever (˚C) at time of hospital admission (Mean ± SD) 38.5 ± 0.89
Use of Antibiotics in past 2 weeks 52 (64.2%)
Use of Anti-Pyretics in past 2 weeks 54 (66.6%)
Use of Anti-Diarrheal in past 2 weeks 3 (3.7%)
�AKUH = Aga Khan University Hospital, AKMCCC = Aga Khan Maternal and Child Care Centre Hyderabad.
https://doi.org/10.1371/journal.pntd.0008682.t001
Fig 2. Age distribution of patient population.
https://doi.org/10.1371/journal.pntd.0008682.g002
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No evidence is available to establish fever clearance time for XDR typhoid. Data from previ-
ous studies for MDR typhoid and fluoroquinolone resistant strains, has shown that deferves-
cence is achieved in less than 7 days[11–14]. These results are in line with the expected time to
defervescence for non-resistant typhoid fever which is 3.5–8 days from initiation of antimicro-
bial therapy[15,16]. Our study was consistent with this range and showed all 3 treatment arm
groups achieving defervescence within the given range. Meropenem is usually considered as
the last option for multi drug resistant gram-negative infections[17] hence there are limited
reports that establish a definitive time to fever clearance for typhoid fever when treated with
meropenem. Literature search reveals 5 fluoroquinolone resistant S.Typhi strains that were
treated with meropenem alone [18,19]or as part of combination therapy[20–22]. Out of these,
only two of the cases achieved defervescence within the expected range[18,19] when treated
with meropenem alone while the remaining three cases required augmentation of meropenem
with another antimicrobial to achieve defervescence[20–22]. More robust data is available for
azithromycin-based therapies where multiple clinical trials have shown that defervescence is
achieved within the expected range [23]. A study by Nair et al suggested that fever clearance
time was longer when patients were treated with azithromycin compared to when patients
Fig 3. Presenting symptoms of patients at time of hospital encounter arranged in descending order of occurrence.
https://doi.org/10.1371/journal.pntd.0008682.g003
Fig 4. Comparison of time to defervescence across different types of antimicrobial therapy for treating XDR
Typhoid patients.
https://doi.org/10.1371/journal.pntd.0008682.g004
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were treated with ceftriaxone[24]. However, in our study, fever clearance time for XDR
typhoid fever patients treated with either azithromycin or meropenem or a combination of
meropenem and azithromycin was similar.
The treatment failure that occurred in azithromycin only group was because of non-resolv-
ing fever even after being given recommended dose and duration of antimicrobial. The fever
resolved after extension of antimicrobial therapy by 5 days. No underlying condition (immune
suppression) or disease complication or non-compliance to therapy was recorded. The treat-
ment failure percentage with azithromycin in our study is consistent with previous clinical tri-
als that have established the efficacy of azithromycin in treating enteric fever[23]. Frenck et al
[25] and Girgis et al[26] explained that the intracellular accumulation of azithromycin within
cells, its secretion into the biliary tree and the long half-life of the drug make it extremely effec-
tive against intracellular infections like enteric fever. Literature, however, is inconclusive when
it comes to the efficacy of meropenem for treating enteric fever. Four case reports point to its
clinical inefficacy based on either relapse of disease[19] or augmentation of meropenem with
another antimicrobial due to unsatisfactory clinical results with meropenem alone[20–22].
Godbole et al[20] discussed the possible treatment failures due to the limited intracellular pen-
etration of meropenem whereas Blumentrath et al[19] explained the treatment failures via the
phenomena of tolerance and persistence exhibited by S.Typhi. In contrast, Munir et al[18]
showed favorable results when treating XDR Typhoid fever with meropenem. Our study
patients showed adequate results when treated with meropenem. Meropenem is a type of β-
lactam antibiotic with inherent stability against ESBLs and possesses a broad-spectrum activ-
ity, these factors could explain the clearance percentage for meropenem[27]. In the group
treated with combination of meropenem and azithromycin, there were 3 treatment failures.
All 3 patients developed systemic complications and unfortunately, one of the patients passed
away. This could be attributed to delay in treatment of both patients because of delayed presen-
tation to the hospital resulting in an unfavorable clinical picture on arrival. The preference
(n = 39; 48%) for using both antibiotics together can likely be explained by the fact that one is
a bacteriostatic (meropenem) and the other is a bactericidal (azithromycin). Past studies have
shown that the combination of ceftriaxone (a bactericidal) with azithromycin (a bacteriostatic)
reduced fever clearance times[28], albeit no study could be found assessing the synergistic
action of meropenem with azithromycin for treating Enteric fever. Case reports by Kleine et al
[21], Godbole et al[20] and Blumentrath et al[19] also suggested that meropenem be combined
with another antimicrobial agent for treating fluoroquinolone resistant and XDR typhoid
fever. Since there are no evidence based clinical guidelines for the treatment of XDR Typhoid,
azithromycin is a good choice since it accumulates intracellularly and has a long half-life.
The longer duration of treatment with azithromycin (6.6 ± 2.7 days) in our study compared
to established protocols[23] was likely due to treating physicians fearing a relapse of the disease
Table 2. Clinical Outcome of patients among the three treatment groups.
Anti-microbial Group N (%) Treated as Inpatients
n (%)
Treatment Failure
n (%)
Duration of Treatment (days)
(Mean ± SD)
Cost of Treatment per
day ‡
Meropenem Only 20
(24.7%)
20 (100%) 0 (0%) 8.1 ± 2.5 13800PKR (US$88.46)
Azithromycin Only 22
(27.2%)
11 (50%) 1 (4.5%) 6.6 ± 2.7 915PKR (US$5.87)
Combination of Meropenem and
Azithromycin
39
(48.1%)
35 (89.7%) 3 (4.5%) Azithromycin: 7.5 ± 3.8
Meropenem: 8.5 ± 4.3
14715PKR (US$94.33)
‡ All prices given in local currency and converted to international dollar according to Bureau of the Fiscal Services Treasury Reporting Rates of Exchange
https://doi.org/10.1371/journal.pntd.0008682.t002
PLOS NEGLECTED TROPICAL DISEASES Response of extensively drug resistant Salmonella Typhi to anti-microbials
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008682 October 15, 2020 7 / 10
and hence giving extended doses of azithromycin. The 1 treatment failure which required
extension of antimicrobial therapy in this group also slightly skewed the mean. For merope-
nem however, there are only limited case reports that guide us about the dosing and duration
of meropenem for XDR typhoid fever or fluoroquinolone resistant typhoid fever. Blumentrath
et al[19] administered it for 10 days where as Kleine et al[21] had to administer it for 22 days
which shows the variance in time meropenem takes to achieve fever clearance. The duration of
treatment with meropenem in our study was similar to duration of treatment of Typhoid fever
with ceftriaxone in past clinical trials[29]. We believe this was due to the similar mechanism of
action of the two antimicrobials (both are bactericidal) and short half-life’s (60mins for mero-
penem vs 330mins for ceftriaxone)[30][31].
Another facet to consider from this study is the cost of therapy of meropenem compared
with azithromycin. Enteric fever is endemic in countries with a lower socio-economic status
due to difficulty in maintaining hygienic conditions. Patients on meropenem therapy must
incur an average daily cost of US$88.46 compared to US$5.87 for azithromycin. For patients
with a lower socio-economic status, the extra cost can prove to be a deterrent in obtaining the
optimum therapy.
Since this is a retrospective study, the information on patient follow ups is limited and the
detailed cost of hospitalization was not recorded. The criteria for assessing which patient
necessitated a specific therapy was also subjective and based on the discretion of the treating
physician Also, we believe the study might have had selection bias because of patients who
were lost to follow up and those who were excluded based on lack of proper data. Furthermore,
as there is an uneven receipt of antibiotics received before presentation to hospital, the average
time to defervescence could have been affected across groups, though none of them had either
received azithromycin or meropenem. The strength of this study was the inclusion of cases
based only on positive blood cultures and not clinical judgement.
In conclusion either azithromycin or meropenem alone or in combination were used for
the treatment of XDR Typhoid in an outbreak setting in Pakistan. The time to defervescence
and the percentage of treatment failures in all groups were similar. Azithromycin is a conve-
nient choice based on cost of therapy and availability in oral form. Clinical trials are needed to
establish days of treatment required and the best treatment options for XDR Typhoid fever.
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